Sponsored By

This activity is supported by an educational grant from Merck & Co.

{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Use of Biosimilars in the Management of Rheumatologic and Gastrointestinal Diseases

Activity Steps

Purpose of Activity

Biosimilars represent new options for the management of patients with rheumatologic and gastrointestinal diseases. The nature of biosimilars and the ways in which they should be used in clinical practice can be confusing to clinicians. An improved understanding of these agents will help to optimize the use of biosimilars.

Learning Objectives/Outcomes

After completing this continuing education activity you will be able to:

  1. Differentiate between biosimilar drugs and generic (bioequivalent) drugs.
  2. Identify FDA's basis for licensure of biosimilars.
  3. Identify available biosimilars indicated for rheumatologic and gastrointestinal disorders.
  4. Indicate how biosimilars should be used in clinical practice.
Price: FREE


  • ANCC 0.75 CH / 0.75 APH

Lippincott Professional Development is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Awarded Advanced Pharmacology Hours

Test Code: BRG0918
Published: September 2018
Expires: 9/3/2021
Required Passing Score: 4/5 (80%)
Authors: Lawrence Herman, MPA, PA-C, DFAAPA; James G. Stevenson, PharmD, FASHP
Topics: Biosimilars